GlassScriptPhysician profile
Robin G Mainwaring
NPI 1043276033
$1,943.30
in general payments reported to CMS, 2019-2025
32 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $364 · 2020: $269 · 2021: $361 · 2022: $408 · 2023: $255 · 2024: $286.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $541.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $540.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $337.10 | 2019-2024 | Veozah, Myrbetriq |
| Boston Scientific Corporation | $238.07 | 2019-2024 | Solyx Sis System |
| Abbvie INC. | $187.25 | 2019-2024 | |
| Daiichi Sankyo INC. | $112.47 | 2019-2022 | |
| Hologic Sales and Service, LLC | $90.67 | 2020-2022 | |
| Exeltis, USA INC. | $85.60 | 2021-2024 | Slynd |
| Evofem Biosciences, INC. | $74.99 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $70.52 | 2019-2022 | |
| Therapeuticsmd, INC. | $65.85 | 2019-2021 | |
| Ascend Therapeutics US, LLC | $59.85 | 2022 | |
| Coloplast Corp | $56.27 | 2021-2022 | |
| C. R. Bard, INC. & Subsidiaries | $40.08 | 2023 | Bd Onclarity |
| Avion Pharmaceuticals | $39.95 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $39.85 | 2020-2023 | Gardasil 9 |
| Bausch Health US, LLC | $39.16 | 2024 | Wellbutrin |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Becton, Dickinson and Company | $38.14 | 2021-2022 | |
| Amgen INC. | $33.36 | 2022 | |
| Aspira Women'S Health INC | $33.28 | 2021 | |
| Organon LLC | $31.80 | 2021-2022 | |
| Axonics, INC. | $31.69 | 2022-2023 | Bulkamid |
| Allergan, INC. | $27.39 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.67 | 2023 | Gammagard |
| Duchesnay USA Incorporated | $22.36 | 2019 | |
| Aroa Biosurgery Incorporated | $21.39 | 2023 | |
| Biocompatibles, INC. | $21.07 | 2019 | |
| Nestle Healthcare Nutrition INC. | $20.45 | 2021 | |
| Genmab U.S., INC. | $20.19 | 2024 | Tivdak |
| Mayne Pharma Commercial LLC | $19.30 | 2023 | |
| Myriad Genetic Laboratories, INC. | $18.71 | 2024 | Myrisk |
| Lupin INC. | $16.50 | 2019 | |
| Shield Therapeutics INC | $13.90 | 2023 | Accrufer |
| Tactile Systems Technology INC | $13.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Mainwaring listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.